Cargando…

The in vivo fate of (225)Ac daughter nuclides using polymersomes as a model carrier

Increasing attention is given to personalized tumour therapy, where α-emitters can potentially play an important role. Alpha particles are ideal for localized cell killing because of their high linear energy transfer and short ranges. However, upon the emission of an α particle the daughter nuclide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruijff, R. M. de, Raavé, R., Kip, A., Molkenboer-Kuenen, J., Morgenstern, A., Bruchertseifer, F., Heskamp, S., Denkova, A. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690960/ https://www.ncbi.nlm.nih.gov/pubmed/31406320 http://dx.doi.org/10.1038/s41598-019-48298-8

Ejemplares similares

Elucidating the Influence of Tumor Presence on the Polymersome Circulation Time in Mice
por: de Kruijff, Robin M., et al.
Publicado: (2019)

Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy
por: Roobol, Stefan J., et al.
Publicado: (2020)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Detailed decay spectroscopy of $^{225}$Ac and its daughters to support its use in medical applications
por: Cocolios, Thomas Elias, et al.
Publicado: (2023)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?
por: de Kruijff, Robin M., et al.
Publicado: (2015)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

Towards reliable production of 225Ac for medical applications: Systematic analysis of the production of Fr, Ra and Ac beams.
por: Dockx, Kristof, et al.
Publicado: (2017)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

Preliminary Therapy Evaluation of (225)Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from (225)Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization
por: Pandya, Darpan N., et al.
Publicado: (2016)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy
por: Wurzer, Alexander, et al.
Publicado: (2017)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Comparison of the biodistribution of $^{225}$Ac and radiolanthanides as citrate complexes
por: Beyer, Gerd-Jürgen, et al.
Publicado: (1990)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
por: Graf, Franziska, et al.
Publicado: (2014)

Gamma counting protocols for the accurate quantification of (225)Ac and (213)Bi without the need for a secular equilibrium between parent and gamma-emitting daughter
por: Castillo Seoane, Dayana, et al.
Publicado: (2022)

mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post–Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis
por: Sathekge, Mike, et al.
Publicado: (2022)

Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with (225)Ac as a Perspective Tool for Combined α-Radioimmunotherapy and Magnetic Hyperthermia of HER2-Positive Breast Cancer
por: Cędrowska, Edyta, et al.
Publicado: (2020)

The application of poorly crystalline silicotitanate in production of (225)Ac
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Estimating (225)Ac yield in thorium metal targets
por: Rahmani, M., et al.
Publicado: (2023)

New measurement of exotic decay of $^{225}$Ac by $^{14}$C emission
por: Guglielmetti, A, et al.
Publicado: (2001)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023)

Nuclear structure effects in the exotic decay of $^{225}$Ac via $^{14}$C emission
por: Bonetti, R, et al.
Publicado: (1993)

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models
por: Sandker, Gerwin Gerhard Wemke, et al.
Publicado: (2023)

Nuclear structure effects in the exotic decay of $^{225}$Ac via $^{14}$C emission
por: Bonetti, R, et al.
Publicado: (1992)

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9d2lbctsjo78h575qlgmr2e8u